Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus.

Photodermatol Photoimmunol Photomed. 1995 Jun;11(3):107-11. Unique Identifier : AIDSLINE MED/96139930
Fotiades J; Lim HW; Jiang SB; Soter NA; Sanchez M; Moy J; Ronald O. Perelman Department of Dermatology, New York University; School of Medicine, NY 10016, USA.

Abstract: To evaluate the efficacy of ultraviolet B (UVB) phototherapy for the treatment of psoriasis in patients infected with human immunodeficiency virus (HIV), the response of 14 patients was compared to that of matched seronegative control individuals. All patients were evaluated prior to treatment (baseline) and after 21 treatments for the extent of total body surface area (TBSA) involvement and the quantification of scale, erythema, and thickness of plaques using a scale of 0 (absent) to 4 (severe). The only concomitant medication allowed was salicylic acid in petrolatum. The cumulative score for scale, erythema, and thickness improved 1.9 +/- 0.5 [mean +/- standard error of mean (SEM)] in the HIV group and 2.4 +/- 0.3 in controls. There was 40.9 +/- 7.3% reduction of TBSA involvement in the former and 38.4 +/- 7.6% reduction in the latter group. None of the differences was statistically significant. There was no statistically significant difference in the response to therapy among various stages of immunosuppression in the HIV group. There was also no deterioration of immune status in this group. UVB phototherapy is an effective treatment for psoriasis in patients infected with HIV. The response is identical to that of matched control individuals.

Keywords: Administration, Cutaneous Adult Antiviral Agents/THERAPEUTIC USE Body Surface Area Case-Control Studies Comparative Study CD4 Lymphocyte Count Dermatitis, Exfoliative/COMPLICATIONS/PATHOLOGY/RADIOTHERAPY Erythema/PATHOLOGY Human *HIV Infections/COMPLICATIONS/DRUG THERAPY/IMMUNOLOGY HIV Seronegativity Immunocompromised Host Keratolytic Agents/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Male Psoriasis/COMPLICATIONS/IMMUNOLOGY/PATHOLOGY/*RADIOTHERAPY Salicylic Acids/ADMINISTRATION & DOSAGE/THERAPEUTIC USE Ultraviolet Rays/CLASSIFICATION Ultraviolet Therapy/*METHODS Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
960530
M9651078

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .